Payment overview · 2025
General Payments
$148.28
7 reported records · 4 companies
Healthcare provider profile · identity verified
Gerald Alan Lee Brown, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · EASLEY, SC · NPI 1760722029
Verified facts
What the public records show
CMS Open Payments records show Gerald Alan Lee Brown, APRN received $148.28 in general payments during 2025 across 7 reported records.
Collegium Pharmaceutical, Inc. accounted for 63.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $93.45 | 63.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.38 | 16.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.74 | 10.6% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $14.71 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $148.28 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $93.45 | 4 | 2025 |
Source payment records
|
|||||
| PENTA Normalized: penta |
Device | Abbott Laboratories | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| TRILURON Normalized: triluron |
Device | Fidia Pharma USA Inc. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 249 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 163 | 52 |
| Gabapentin | Gabapentin | 149 | 57 |
| Eliquis | Apixaban | 136 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 39 |
| Furosemide | Furosemide | 102 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 31 |
| Omeprazole | Omeprazole | 88 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 51 |
| Losartan Potassium | Losartan Potassium | 78 | 29 |
| Trazodone Hcl | Trazodone Hcl | 78 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 37 |
| Mirtazapine | Mirtazapine | 67 | 29 |
| Lorazepam | Lorazepam | 60 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 28 |
| Potassium Chloride | Potassium Chloride | 59 | 40 |
| Klor-Con 10 | Potassium Chloride | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 37 |
| Lisinopril | Lisinopril | 49 | 26 |
| Xarelto | Rivaroxaban | 47 | 11 |
| Carvedilol | Carvedilol | 46 | 21 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 25 |
| Glipizide | Glipizide | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | 14 |
| Sertraline Hcl | Sertraline Hcl | 37 | 12 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | 18 |
| Tramadol Hcl | Tramadol Hcl | 35 | 20 |
| Allopurinol | Allopurinol | 33 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Torsemide | Torsemide | 28 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 24 | 17 |
| Donepezil Hcl | Donepezil Hcl | 24 | 13 |
| Lacosamide | Lacosamide | 24 | suppressed |
| Lactulose | Lactulose | 24 | 16 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Prednisone | Prednisone | 24 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Famotidine | Famotidine | 23 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | 16 |
| Ingrezza | Valbenazine Tosylate | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Finasteride | Finasteride | 15 | 11 |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 14 | 14 |
| Atenolol | Atenolol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | 11 |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | 13 |
| Metformin Hcl | Metformin Hcl | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148.28 · 7 records | Collegium Pharmaceutical, Inc. | Belbuca, HYMOVIS, INGREZZA, PENTA, TRILURON | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Neurocrine BioSciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error